Endpoint Determination Research Articles

Case Studies on the use of Microsampling for Nonclinical Studies in Pharmaceutical Drug Discovery and Development.

The implementation of microsampling approaches for use in nonclinical discovery and development pharmaceutical studies can have a major impact on improving animal ethics through the use of fewer animals and less invasive procedures for the collection of toxicokinetic and pharmacokinetic samples. In addition, the approach offers the opportunity for obtaining improved quality of data for these studies. This can include the determination of additional timepoints and endpoints, and the ability to obtain exposure data from the same animals utilized to measure other study endpoints. This manuscript presents a number of cases where a variety of microsampling approaches have been successfully implemented by a number of organizations and serves as a guide for those considering the use of microsampling approaches as part of their drug discovery and development programs, as the adoption of these approaches are not yet universal.

ELISA-R: an R-based method for robust ELISA data analysis.

Enzyme-linked immunosorbent assay (ELISA) is a technique to detect the presence of an antigen or antibody in a sample. ELISA is a simple and cost-effective method that has been used for evaluating vaccine efficacy by detecting the presence of antibodies against viral/bacterial antigens and diagnosis of disease stages. Traditional ELISA data analysis utilizes a standard curve of known analyte, and the concentration of the unknown sample is determined by comparing its observed optical density against the standard curve. However, in the case of vaccine research for complicated bacteria such as Mycobacterium tuberculosis (Mtb), there is no prior information regarding the antigen against which high-affinity antibodies are generated and therefore plotting a standard curve is not feasible. Consequently, the analysis of ELISA data in this instance is based on a comparison between vaccinated and unvaccinated groups. However, to the best of our knowledge, no robust data analysis method exists for "non-standard curve" ELISA. In this paper, we provide a straightforward R-based ELISA data analysis method with open access that incorporates end-point titer determination and curve-fitting models. Our modified method allows for direct measurement data input from the instrument, cleaning and arranging the dataset in the required format, and preparing the final report with calculations while leaving the raw data file unchanged. As an illustration of our method, we provide an example from our published data in which we successfully used our method to compare anti-Mtb antibodies in vaccinated vs non-vaccinated mice.

Development of a new method for analyzing the behavior of rapidly dissolving films in contact with liquids

Oral Thin Film (OTF) is a promising dosage form, easy to use and patient-friendly drug delivery systems suitable for every consumer profile. This dosage form ensures safety, stability, and acceptability of the drug, that's why it can be a good alternative for tablets and capsules for children and elderly therapies. As no detailed monography of OTFs including characterization methods and uniform requirements has been presented in any of the pharmacopoeias to date, this study focuses on the development of an innovative analyzing method to characterize the OTF behavior and particularly to determine its disintegration time by goniometry. These parameters are key for the development of OTFs and for studying, at an early stage, the impact of formulation and process variables on product quality and impacting Critical Quality Attributes (CQA) by a Quality by Design approach.Different model OTF preparations were investigated as models to determine the suitability of the disintegration test systems. These placebos OTF were used to compare the disintegration times obtained by the tablets pharmacopeial method (conducted in 800 mL of distilled water) and the novel proposed method. As expected, the disintegration times determined by the proposed method were similar than those obtained by the conventional disintegration test. Moreover, they seem more reliable to the in vivo behavior because of the small amount of solvent used. The experiments showed acceptable reproducibility (low variation within sample replicates due to a well-defined determination of the measurement endpoint). This method provides clear endpoint detection and is applicable for different types of OTFs based on different polymers. Moreover, a better understanding of the physical-chemical properties of oral thin films towards water could be obtained. This new method of analysis could provide a valuable approach to the development of new OTF formulas, thanks to the different information that can be obtained, such as critical energy, free energy and polar and dispersive components.

Ultrasonic technology for predicting beef thawing degree and endpoint

Precise control and accurate endpoint determination in the thawing of frozen beef are vital for maintaining its quality and safety in the food industry. Traditional thawing methods, which are time-controlled, often lead to inconsistencies like under or over-thawing, adversely affecting texture, color, nutritional value, and increasing the risk of microbial contamination. This study introduces a novel, non-destructive approach using ultrasonic signals and ultrasonic velocity for the quantification of beef thawing. It involves analyzing thermal images of beef cross-sections to assess thawing levels and gathering ultrasonic data at various thawing stages. Machine learning algorithms, including KNN, ANN, Extra-Trees, and LightGBM, were employed to develop prediction models that accurately identify the thawing endpoint. The models exhibit high accuracy, with R^2 values exceeding 0.9, some reaching as high as 0.986. This method represents a significant advancement in non-destructive quality control, enhancing safety and quality management in the beef processing sector.

Comparative histologic evaluation of teeth decalcified by conventional method versus microwave induced decalcification

Abstract Introduction: Complete demineralization of hard tissues with preservation of organic components to retain their tissue architecture and to obtain thin section for histological examination is done by a process known as “decalcification”. Tooth decalcification may be achieved by subjecting the tissue to a decalcifying chemical agent and employing heat, vacuum, or electric current to enhance the procedure. Completion of decalcification is adjudged by determination of end-point. Histological examination of hard tooth tissues and pulp is essential for diagnosis of developmental pathologies, pulp pathologies, and forensic odontology analysis as well as for research purpose. Aim: In our study, we studied the time consumed for decalcification procedure by conventional decalcification method and with the microwave-assisted decalcification method for teeth, using 5% nitric acid, 5% trichloracetic acid, and 14% EDTA (Ethylenediaminetetraacetic acid), respectively, along with morphological preservation of dentin and pulp tissue by analyzing preservation of their issue structure (pulp shrinkage, odontoblastic layer damage) and staining efficacy (patchy staining) for the three types of decalcifying agents used. Materials and Method: The sample for this study included 120 freshly extracted teeth consisting of teeth of mandibular dentition. Samples were divided into two study groups: Group I: Decalcified by Conventional method Group II: Decalcified by Microwave method. Each group consisted of, three sub-groups employing a different decalcifying agent from among the three decalcifying agents used, that is, 5% nitric acids, 5% trichloroacetic acid, and 14%EDTA respectively. Result: The difference in speed of decalcification for both groups showed significant result. In either group, decalcification was fastest using 5% nitric acid. The difference in number of decalcified teeth sections showing shrinkage of pulp was not statistically significant for both groups. Damaged odontoblastic layer was evident only in the teeth treated with 5% nitric acid by microwave method. Patchy staining was observed in a few samples of all sample groups except those decalcified with EDTA by conventional method but the results were not statistically different on intercomparison. Discussion and Conclusion: Our results are similar to those of previous studies and we found that microwave method is an option that can reduce the time of decalcification. Tooth tissue morphology also was noted to be well preserved with 5% trichloracetic acid and 14% EDTA in comparison to 5% Nitric acid.

Online monitoring for extraction of Tibetan medicine Meconopsis quintuplinervia regel. Based on near infrared spectroscopy coupled with chemometrics

The extraction process plays a crucial role in the production of Tibetan medicines. This study focused on assembling a set of online near-infrared (NIR) spectroscopy detection devices for the extraction of medicinal herbs. The original infrared device was transformed into an online detection system. After evaluating the stability of the system, we applied online NIR spectroscopy monitoring to the flavonoid contents (total flavonoids, quercetin-3-O-sophoroside, and luteolin) of Meconopsis quintuplinervia Regel. during the ultrasonic extraction process and determined the extraction endpoint. Nine batches of samples were employed to construct quantitative and discriminant models, half of the remaining two batches of samples are used for external verification. Our research shows that the residual predictive deviation (RPD) values of total flavonoids, quercetin-3-O-sophoroside and luteolin models exceeded 2.5. The R values for external verification of the three ingredients were above 0.9, with RPD values generally exceeding 2 and RSEP values within 10 %, demonstrating the model’s strong predictive performance. Most of the extraction endpoints of the flavonoid components in M. quintuplinervia ranged from 18 to 58 min, with high consistency between the predicted extraction endpoints of the external validation, suggesting accurate determination of extraction endpoints based on predicted values. This study can provide a reference for the online NIR spectroscopy quality monitoring of the extraction process of Chinese and Tibetan herbs.

Abstract PO5-05-03: Phase 1/2 Dose Expansion Study Evaluating First-In-Class eIF4A Inhibitor Zotatifin in Patients with ER+ Metastatic Breast Cancer

Abstract Background Zotatifin (eFT226) is a first-in-class, potent and sequence selective inhibitor of RNA helicase eIF4A that promotes a stable mRNA:eIF4A:drug ternary complex at specific polypurine motifs present within the 5’-UTR of select transcripts, thereby blocking production of the encoded proteins. In preclinical models zotatifin treatment simultaneously down-regulated translation of numerous oncogenes including CDK4, ERα, ERBB2, KRAS, and CCND1. Previous clinical research has demonstrated the activity of zotatifin in combination with other agents in ER+ metastatic breast cancer (MBC). Methods Part 1 is a 3+3 dose escalation portion of the protocol followed by Part 2 as a Simon’s two-stage design in patients with ER+ MBC enrolled at the recommended phase 2 dose (RP2D) of zotatifin (0.07 mg/kg IV two weeks on/one week off) in combination with fulvestrant (ful) and abemaciclib (abema) (Z+F+A). Part 1a and Part 1b are 3+3 dose escalation portions evaluating zotatifin in combination with ful (Z+F) at QW IV and Q2W IV dosing schedules, respectively. Key eligibility criteria included at least one line of therapy for advanced/metastatic disease, progression on hormone therapy, and in addition, the Z+F cohorts required prior CDK 4/6 inhibitor (CDKi). Primary endpoint of Part 1a/1b was determination of RP2D and primary endpoint of part 2 was objective response rate (ORR) per RECIST v1.1. Additional endpoints included safety, progression-free survival (PFS) and other efficacy analyses, and characterization of pharmacodynamic (PD) markers and pharmacokinetics. Results As of a data cut-off of July 6, 2023, 20 pts were enrolled in the Z+F+A cohort and had a median of four prior metastatic lines of therapy. In 19 evaluable pts in Z+F+A cohort, there were four confirmed partial responses (PR), one unconfirmed PR, and 10 pts with best overall response (OR) of stable disease (SD). All pts with PR/unconfirmed PR received prior CDKI, ful, and chemotherapy for MBC. Confirmed PRs were observed in patients with and without mutations in ESR1 and PIK3CA. mPFS, while not yet mature, exceeds 20 weeks. In Z+F+A the most common adverse events (AEs) were diarrhea (80%, all grades (Gr)) and nausea (75%, all Gr 1/2) and the most common Gr 3/4 AE was diarrhea (15%). In Z+F cohorts of 0.07 mg/kg QW (n=3), 0.1 mg/kg Q2W (n=3), and 0.14 Q2W (n= 2) there were no dose-limiting toxicities or Gr 5 adverse events (AEs). There was one confirmed PR and one SD in 0.1 and 0.14 mg/kg Q2W cohorts, respectively, and no PR or SD in the 0.07 mg/kg QW cohort. In Z+F+A, 9 pts had paired pre- and on-treatment ctDNA analyzed by Guardant assay. Of the remaining 11 pts, 4 came off study prior to scheduled collection of the on-treatment sample and 5 had unavailable samples. Of the 9 patients with paired samples, 8 had ctDNA decreases of >50%, all of whom had SD or PR. In the Z+F Q2W cohort, 2 of 3 patients had ctDNA decreases >50%, one of whom had a PR. Reduction below the limit of detection was seen for mutant alleles in ESR1, PIK3CA and other genes with potential to confer resistance to endocrine therapy. Conclusion Z+F+A showed encouraging efficacy in heavily pretreated ER+ MBC patients, with results that compare favorably to other treatment options available after progression on CDKi plus endocrine treatment. Efficacy was seen independent of ESR1 or PIK3CA mutations, suggesting the potential to treat a broad, unrestricted patient population. Initial results with Z+F Q2W dosing are encouraging and support continued dose escalation of this regimen. Citation Format: Ezra Y. Rosen, Manish Sharma, David Berz, Jennifer Caswell-Jin, Georgina Fulgar, Mark Densel, Gary Chiang, Samuel Sperry, Douglas Warner, Funda Meric-Bernstam. Phase 1/2 Dose Expansion Study Evaluating First-In-Class eIF4A Inhibitor Zotatifin in Patients with ER+ Metastatic Breast Cancer [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO5-05-03.

Posterior endpoint determination of the lumbar pedicle central axis on the anterior–posterior fluoroscopic image for pedicle screw insertion

The transpedicular procedure has been widely used in spinal surgery. The determination of the best entry point is the key to perform a successful transpedicular procedure. Various techniques have been used to determine this point, but the results are variable. This study was carried out to determine the posterior endpoint of the lumbar pedicle central axis on the standard anterior–posterior (AP) fluoroscopic images. Computer-aided design technology was used to determine the pedicle central axis and the posterior endpoint of the pedicle central axis on the posterior aspect of the vertebra. The standard AP fluoroscopic image of the lumbar vertebral models by three-dimensional printing was achieved. The endpoint projection on the AP fluoroscopic image was determined in reference to the pedicle cortex projection by the measurements of the angle and distance on the established X–Y coordinate system of the radiologic image. The projection of posterior endpoint of the lumbar pedicle central axis were found to be superior to the X-axis of the established X–Y coordinate system and was located on the pedicle cortex projection on the standard AP fluoroscopic image of the vertebra. The projection point was distributed in different sectors in the coordinate system. It was located superior to the X-axis by 18° to 26° at L1, while they were located superior to the X-axis by 12° to 14° at L2 to L5. The projections of posterior endpoints of the lumbar pedicle central axis were located in different positions on the standard AP fluoroscopic image of the vertebra. The determination method of the projection point was helpful for selecting an entry point for a transpedicular procedure with a fluoroscopic technique.

Clinical validation of grass pollen exposure chamber in patients with allergic rhinitis triggered by timothy grass.

The fluctuation in concentrations of airborne allergens frequently presents a challenge to assessing the efficacy of allergen immunotherapy (AIT) in 'field' studies. Allergen exposure chambers (AECs) are specialized medical installations developed to expose individuals to allergens at defined and consistent concentrations under a controlled environment. The aim of the study was to validate the provocation test with timothy grass pollen as well as to assess its safety in the AEC in patients with allergic rhinitis. In the ALLEC® AEC, varying concentrations of timothy grass pollen were dispersed. Allergic symptoms were measured by total nasal symptom score (TNSS), acoustic rhinometry, peak nasal inspiratory flow (PNIF) and nasal discharge volume. Lung function, assessed through peak expiratory flow rate (PEFR) and forced expiratory volume in the first second (FEV1), was used to evaluate safety. The consistency of the test was proved by the stability of environmental conditions, including temperature, humidity and CO2 levels, as well as constant concentrations of grass pollen at predetermined levels ranging from 1000 to 10,000 particles per cubic meter (p/m3). Allergic individuals developed symptoms at concentrations of 3000 p/m3 and above, across all measured endpoints. Lung function was not affected throughout all the challenges. The reproducibility of symptoms was confirmed throughout the tests. The concentration of 8000 p/m3 together with a challenge duration of 120 min was found to be optimal. The study demonstrates that the ALLEC® grass pollen exposure chamber provides a reliable and safe method for inducing repeatable symptoms in patients with allergic rhinitis. This approach can be effectively applied for allergy diagnostics and clinical endpoint determination during AIT.

Mid-infrared spectroscopic identification of the right-baked rhubarb for ulcerative colitis therapy

Clinical and experimental evidences have confirmed the significant therapeutic effects of rhubarb on ulcerative colitis (UC), but the strong purgative function of rhubarb also aggravates UC symptoms such as bloody diarrhea. Stir-baking to scorch is a traditional Chinese medicinal processing method that can eliminate the adverse purgative function while keep or even enhance the UC therapeutic function of rhubarb. However, the under-baked rhubarb still have the undesirable purgative function, but the over-baked rhubarb may lose the required medicinal functions. Therefore, the determination of the right endpoint is the primary quality concern about the baking process of rhubarb. In this research, typical anthraquinone compounds and mid-infrared (MIR) spectra were recruited to determine the best baking degree of rhubarb for UC therapy. Raw rhubarb slices were baked at 180 °C with rotation to prepare the rhubarbs with different baking degrees. The right-baked rhubarb was defined according to the UC therapeutic responses as well as the traditional color criterion. Referring to the typical anthraquinone compounds in rhubarb slices and extracts, the baking degree of rhubarb may be assessed by the conversion ratio of anthraquinone glycosides to anthraquinone aglycones. MIR spectra showed the gradual decompositions of organic compounds including anthraquinone glycosides and tannins during the baking process. Rhubarbs with different baking degrees can be distinguished clearly by MIR-based principal component analysis. In conclusion, the ratio of anthraquinone glycosides to anthraquinone aglycones may be a reasonable chemical indicator of the right-baked rhubarb. Meanwhile, MIR spectroscopy can identify the right-baked rhubarb simply and rapidly.

Dynamic sampling in autonomous process optimization.

Autonomous process optimization (APO) is a technology that has recently found utility in a multitude of process optimization challenges. In contrast to most APO examples in microflow reactor systems, we recently presented a system capable of optimization in high-throughput batch reactor systems. The drawback of APO in a high-throughput batch reactor system is the reliance on reaction sampling at a predetermined static timepoint rather than a dynamic endpoint. Static timepoint sampling can lead to the inconsistent capture of the process performance under each process parameter permutation. This is important because critical process behaviors such as rate acceleration accompanied by decomposition could be missed entirely. To address this drawback, we implemented a dynamic reaction endpoint determination strategy to capture the product purity once the process stream stabilized. We accomplished this through the incorporation of a real-time plateau detection algorithm into the APO workflow to measure and report the product purity at the dynamically determined reaction endpoint. We then applied this strategy to the autonomous optimization of a photobromination reaction towards the synthesis of a pharmaceutically relevant intermediate. In doing so, we not only uncovered process conditions to access the desired monohalogenation product in 85 UPLC area % purity with minimal decomposition risk, but also measured the effect of each parameter on the process performance. Our results highlight the advantage of incorporating dynamic sampling in APO workflows to drive optimization toward a stable and high-performing process.

A road map for the treatment of pediatric diffuse midline glioma

Recent clinical trials for H3K27-altered diffuse midline gliomas (DMGs) have shown much promise. We present a consensus roadmap and identify three major barriers: (1) refinement of experimental models to include immune and brain-specific components; (2) collaboration among researchers, clinicians, and industry to integrate patient-derived data through sharing, transparency, and regulatory considerations; and (3) streamlining clinical efforts including biopsy, CNS-drug delivery, endpoint determination, and response monitoring. We highlight the importance of comprehensive collaboration to advance the understanding, diagnostics, and therapeutics for DMGs.

Optimizing Immunoglobulin Replacement Therapy for Patients with B-Cell Malignancies and Hypogammaglobulinemia: The Investigator-Initiated, International, Randomized Phase II/III Rational Platform Trial, and the Rationalise (STOP IgRT) Domain

Background & significance: Hypogammaglobulinemia is common in patients with chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL) and multiple myeloma (MM), and associated with an increased risk of serious infection. Immunoglobulin (Ig) replacement therapy (IgRT) is widely used to reduce this risk, but national guidelines and clinical practice are variable. Supportive care and treatment regimens have evolved since evidence supporting IgRT was published. Ig is expensive, in limited supply, and with increasing use of B-cell-depleting therapies in this setting, and prolonged survival, demand continues to grow globally.It is not clear when to start IgRT, nor the optimal duration or dose. Some jurisdictions require a trial of oral antibiotics (Abx) prior to starting IgRT, and some recommend a trial of stopping IgRT in stable patients. More data are needed on the benefits, risks and costs of these different approaches. Hypothesis: For the prevention of infection in adults with hypogammaglobulinemia due to CLL, NHL or MM prophylactic oral Abx, or a strategy of patient-held emergency Abx supply only, are non-inferior to IgRT. Study design: The RATIONAL platform trial is an investigator-initiated, international (Australia, New Zealand, Canada), phase II/III randomized controlled trial (RCT) with 3 domains: (1) the RATIONALISE ‘STOP Ig’ study (ACTRN 12622000359730), now recruiting; (2) a ‘START Ig’ study comparing IgRT or Abx in patients eligible to start IgRT; and (3) a DOSE study comparing IgRT at 0.25 vs 0.4g/kg/month (m). The platform includes qualitative, biological (immune profile, microbiome) and health economics studies. In the RATIONALISE (‘STOP Ig‘) domain, patients are randomized 1:1:1 to either: - Arm A: Stop Ig and commence prophylactic oral Abx: Daily trimethoprim-sulfamethoxazole (co-trimoxazole) 160mg/800mg (doxycycline 100mg/day if co-trimoxazole hypersensitive). - Arm B: Stop Ig. Keep amoxycillin/clavulanic acid 1750-2000mg/250mg and ciprofloxacin 750mg on hand for initial use for symptoms of infection, with immediate clinical review. Clindamycin 600mg if penicillin hypersensitive. - Arm C: Continue Ig: IV q 4±1 wks at 0.4g/kg, modified to achieve IgG trough of at least lower limit of age-specific serum IgG reference range, OR subcutaneous (SC), dosed in line with site/country criteria. Inclusion criteria: ≥18y with CLL, NHL or MM, receiving IgRT (IV or SC) for >6m, eligible for Ig cessation in opinion of treating clinician, life expectancy >12m, able to give informed consent and comply with each of the trial arms. Exclusion criteria: Prior/planned allogeneic transplantation. Major infection (≥Grade 3 CTCAE v5) in preceding 3m, and/or current active infection requiring antimicrobial treatment. Already on daily Abx for purpose of preventing bacterial infection (may have antiviral, antifungal, PJP prophylaxis). Intolerance of all trial Abx options.Communication, compliance or logistics likely to limit ability to take prophylactic or emergency Abx, or obtain urgent medical attention for infection symptoms. Pregnant/breastfeeding. Creatinine clearance <30 mL/min. Splenectomy. Enrolment deemed not in patient's interest. Primary endpoint: Event-free survival, from randomization until ≥Grade 3 infection or death from any cause. Secondary endpointsinclude other infectious outcomes to 12m, time free from hospitalization and therapeutic Abx, Abx resistance, QoL, trough Ig levels, proportion of patients who stop Ig and re-start, costs, adverse events. End-point determination: Study is not blinded, but infections and adverse events are adjudicated by an independent, blinded outcome adjudication committee. Planned treatment duration in all arms is 12m, with follow-up via established clinical registries. Statistical methods: STOP Ig domain has an initial cap of 300 patients and uses flexible Bayesian monitoring involving frequent interim analyses where interventions may be stopped early to declare proof-of-concept/efficacy or inferiority, or accrual may expand. Stratified by diagnosis. Progress/Summary: This novel international platform trial will inform infection prevention strategies for the growing population of patients with CLL, NHL or MM living with hypogammaglobulinemia. The first domain ('STOP Ig') is now open at 4 sites, with the first patients recruited. To our knowledge, this is the first trial of 'stopping' Ig in this setting.

2108. In-vitro Activity of Five Novel Anti-Fungal Compounds Against Thirty-Two Strains of Talaromyces marneffei

Abstract Background Talaromyces marneffei (Tm) is a thermally dimorphic fungus causing invasive mycosis in human immunodeficiency virus (HIV) infected patients in Southeast Asia and is a leading cause of AIDS-related deaths in this region with mortality on anti-fungal therapy as high as 30%. The limited options, routes of administration, and toxicity of antifungals with established efficacy against Tm calls for assessment of efficacy for additional antifungals against Tm. Here we evaluate the in-vitro efficacy of 5 novel anti-fungal agents against 32 clinical strains of Tm. The agents tested include ibrexafungerp, two manogepix compounds (APX001A and APX2039), olorofim, and oteseconazole. Methods 32 Tm isolates were cultured from clinical samples from patients in Vietnam and identified as Tm by standard morphological characteristics. Inocula were prepared from these clinical samples in conjunction with CLSI standards and plated onto 96-well microplates. Concentrations for each drug ranged from 0.008 µg/mL to 4 µg/mL. AlamarBlueTM, a resazurin-based cell viability indicator dye, was added to the drug-inoculum solution. Use of this reagent enabled utilization of a microplate fluorescence intensity(FI) reader to objectively identify the designated MIC endpoint of 50% inhibition of growth. Methods (Figure 1). MIC endpoint determination using AlamarBlue indicator dye method. Clinical Tm isolates were thawed and plated on Yeast Peptone Dextrose (YPD) agar and grown for 3-5 days at 37°C. Isolates were then sub-cultured on fresh YPD agar and allowed to grow for 3 days prior to inoculum preparation. Inocula were prepared according to CLSI standards. Following suspension in solution, inocula were diluted in PBS until an optical density (OD) of 0.5 to 0.6 was achieved. Inocula were further diluted in RPMI + MOPS and added to the drug-dilution microplates to achieve a final concentration of 1000-5000 cells/mL. After incubation at 37°C for 24 hours, AlamarBlue was added to all wells. Following incubation for an additional 48 hours, fluorescence intensity (FI) was measured using a microplate reader to determine the MIC endpoint of 50% inhibition of fungal growth. Results Of the drugs tested, olorofim showed the highest activity against the 32 isolates, with MICs consistently ≤ 0.008 µg/mL. This was followed by oteseconazole with MICs between ≤ 0.008 and 0.031 µg/mL APX001A with MICs between 0.031 and 0.25 µg/mL and APX2039 with MICs between 0.25 and 4 µg/mL. Ibrexafungerp had the broadest MIC distribution with MICs between 0.063 and 4 µg/mL. Figure 2/Table 1. MIC Endpoint Distribution. Figure 2 shows a scatter plot of MIC endpoints for each drug. Error bars demonstrate the geometric mean and 95% confidence intervals. Table 1 illustrates the MIC endpoint distribution in a graded heat map format. In addition, the absolute values of the geometric mean (GM), mode, MIC50, and MIC90 are displayed at the right side of the table. Both Figure 2 and Table 1 illustrate high efficacy for olorofim and oteseconazole, with low MIC endpoints consistent across the 32 isolates. The manogepix compounds(APX001A and APX2039) demonstrate surprisingly contrasted performance against Tm, despite the similar chemical structure and identical mechanism of action of the drugs. APX001A had significantly lower MIC endpoints compared to APX2039. Ibrexafungerp had the broadest range of MIC endpoints from 0.063 to 4µg/mL and the highest MIC50 and MIC90 of all the drugs. However, a significant proportion of isolates were highly susceptible to the drug. Conclusion In-vitro activity of the 5 drugs tested against the 32 Tm strains was variable, but all should be considered potential candidates for treating Tm infection. To further evaluate the potential role of each drug in treating Tm infection, the next step should be to evaluate each in in-vivo models. Disclosures All Authors: No reported disclosures

Reproducibility, reliability, and regulatory relevance of plant visual injury assessments.

The registration of herbicides in the European Union requires an assessment of risks to nontarget terrestrial plants (NTTPs). Regulatory plant studies are performed to determine risk-assessment-relevant endpoints (50% effect rate) for quantitative parameters, mostly biomass and survival. Recently, the European Food Safety Authority stated that endpoints for qualitatively assessed plant visual injuries (PVIs) such as necrosis, chlorosis, and so forth should be considered for the risk assessment as equal to endpoints derived from quantitatively determined parameters. However, the lack of guidance in the NTTP test guidelines on how to assess PVI and how to derive a statistically meaningful endpoint for PVI makes their use in risk assessments challenging. To evaluate and improve the reliability, reproducibility, and regulatory relevance of PVI assessments in NTTP studies, the PVI Working Group was formed in 2022 within the SETAC Plant Interest Group. In a first exercise, research needs, guidance gaps, and shortcomings in current methodologies were identified and are presented together with recommendations for a future, validated, and harmonized method for the assessment of PVI. Survey results revealed a high variability in how PVI are currently assessed, and that the reliability of these data is unclear. Under current conditions, the PVI data can rather be seen as supportive information instead of using the data for the statistically sounddetermination of a regulatory endpoint. Consequently, standardization and harmonization of procedures for the assessment of PVI are needed. An improved scoring methodology should be developed that allows for a precise, statistically sound endpoint determination. Regarding the regulatory relevance of PVI, further research is required to assess the biological meaning of PVI data and how this is connected to the regulatory requirements and protection goals. Last but not least, guidance is required on how to evaluate the historically available PVI data that are based on various assessment methodologies. Integr Environ Assess Manag 2024;20:915-923. © 2023 The Authors. Integrated Environmental Assessment and Management published by Wiley Periodicals LLC on behalf of Society of Environmental Toxicology & Chemistry (SETAC).

Statistical and dynamic model of surface morphology evolution during polishing in additive manufacturing

Many industrial components, especially those realized through 3D printing undergo surface finishing processes, predominantly, in the form of mechanical polishing. The polishing processes for custom components remain manual and iterative. Determination of the polishing endpoints, i.e., when to stop the process to achieve a desired surface finish, remains a major obstacle to process automation and in the cost-effective custom/3D printing process chains. With the motivation to automate the polishing process of 3D printed materials to a desired level of surface smoothness, we propose a dynamic model of surface morphology evolution of 3D printed materials during a polishing process. The dynamic model can account for both material removal and redistribution during the polishing process. In addition, the model accounts for increased material flow due to heat generated during the polishing process. We also provide an initial random surface model that matches the initial surface statistics. We propose an optimization problem for model parameter estimation based on empirical data using KL-divergence and surface roughness as two metrics of the objective. We validate the proposed model using data from polishing of a 3D printed sample. The procedures developed makes the model applicable to other 3D printed materials and polishing processes. We obtain a network formation model as a representation of the surface evolution from the heights and radii of asperities. We use the network connectivity (Fiedler number) as a metric for surface smoothness that can be used to determine whether a desired level of smoothness is reached or not.

Process understanding and monitoring: A glimpse into data strategies for miniaturized NIR spectrometers

BackgroundThe implementation of process analytical technologies (PAT) has gained attention since 2004 when its formal introduction through the U.S. Food and Drug Administration was introduced. Manufacturers that need to evaluate the employment of new monitoring systems could face different challenges: identification of suitable sensors, verification of data meaning, evaluation of several statistical strategies to obtain insights about data and achieve process understanding and finally, the actual possibilities for monitoring. Kefir fermentations were chosen as an example because of the chemical and physical transformations that occurred during the process, which could be common to several other fermentation processes. In order to pave the way for monitoring establish the information contained in the data and find the right tools for extracting them is of extreme importance. Strategies to identify different experimental conditions in the spectra acquired with a miniaturized NIR (1350-2550 nm) during process occurrence were addressed. ResultsThe study aims to offer insights into good practices and steps to pave the way for process monitoring with handheld NIR data. The main aspects of interest for batch processes in preliminary evaluations were investigated and discussed. On the one hand, process understanding and, on the other, the possibilities for process monitoring and endpoint determination were examined. The combination of different statistical tools allowed the extraction of information from the data and the identification of the link between them and the chemical and physical changes during the process. In addition, insights into the spectra characteristics in the studied spectroscopic range for kefir fermentation were reported. SignificanceThe capabilities for miniaturized NIR spectra to represent and statistical strategies to characterize different experimental conditions in a real case fermentation occurrence were proved. The strengths and limitations of some of the common approaches to catch changes in fermentation condition were highlighted. For the various statistical approaches, the chances offered in the research and development stages and to set the scene for monitoring and end-point detection were explored.

Optimization of radial extrusion and pellet coating processes using PAT approaches

FDA's initiative Pharmaceutical CGMPs for the 21st century opened the door for introduction of several risk based approaches in pharmaceutical industry. One significant advancement that has emerged is the implementation of process analytical technology (PAT), which has opened doors for understanding and controlling complex technological processes. Two such processes, radial extrusion and pellet coating, offer a solid foundation for the application of PAT tools due to their numerous critical process parameters. The aim of the first part of the study was to optimize the neutral pellet production to produce the pellets with properties desired for successful film coating using design of experiments (DoE). In the second part the optimized pellets underwent film coating and the coating quantity was predicted in real or near real-time using in-line and at-line NIR probes and the performance of both probes was compared.The desired properties of the pellets, narrow particle size distribution, high sphericity and high process yield, were successfully achieved. Models for film coating quantity prediction using in-line and at-line NIR probe were successfully calibrated and tested by coating two additional batches. Despite the limited sample size for model calibration, at-line NIR exhibited excellent prediction performance and enabled accurate determination of process end-point. The coating quantity determined by UV/VIS spectroscopy in both test batches deviated by less than 2.0 % from the target value. However, the in-line NIR probe, primarily due to its inferior spectral resolution, displayed a slightly lower quality of the calibrated model and notable overprediction for the tested batches.

Optical methods for caries detection and determination of caries removal end points.

The modern standard in dentistry requires minimally invasive treatment, as it allows preserving the teeth vitality. The purpose of this study was to evaluate the possibility of laser spectroscopy and quantitative light-induced fluorescence to determine the caries removal end point. Materials and methods: the study was conducted on ten third molars extracted for medical reasons. Measurements were carried out at different stages of preparation of the carious cavity using laser spectroscopy (DIAGNOdent-pen) and quantitative light-induced fluorescence (Qraypen). Results: both methods were effective in differentiating affected and infected dentin. The following indicators of carious tissues were obtained. DIAGNOdent-pen: carious enamel — 28.8±8; soft dentin — 68.3±14; firm dentin (pigmented and non-pigmented) — 23.7±8 and 9.2±3 respectively; healthy dentin (hard) — 4.7±3. For Qraypen: carious enamel — ΔF=25.7±9, ΔR=26; soft dentin — ΔF=26.6±9 ΔR=28.75; firm dentin — ΔF=18.4±9, ΔR=0—10 (no difference between pigmented and non-pigmented was observed); healthy dentin (hard) — ΔF=13.7±8, ΔR=0. Conclusion: methods of laser spectroscopy and quantitative light-induced fluorescence can be used for diagnostics and to assess the quality of preparation of carious cavities, effectively detect fissure caries and selectively remove infected dentin.

Effects of combination antihypertensive therapy on intracardiac hemodynamics and blood vessels in patients with coronary heart disease, post-infarction cardiosclerosis and arterial hypertension

The aim of the work is to assess the effectiveness of prescribing a fixed-dose combination of amlodipine with the ACE inhibitor lisinopril or with the angiotensin 2 receptor blocker valsartan in patients with coronary artery disease, acute coronary syndrome with hypertensive disease regarding the impact on the structural and functional parameters of the heart and extracranial branches of the brachiocephalic arteries. Materials and methods. General clinical examination of 108 patients with postinfarction cardiosclerosis and hypertension was done within 12 months. The patients were allocated to two groups. Patients in the first group (n = 50) were assigned a fixed-dose combination of lisinopril and amlodipine (20 mg and 5 mg, respectively), and patients in the second group (n = 58) received a fixed-dose combination of valsartan with amlodipine (160 mg and 5 mg, respectively). The patients were monitored for 12 months, including general clinical examinations, measurements of office blood pressure (BP), 24-hour BP monitoring, echo-dopplerographic examination of the heart and brachiocephalic arteries, determination of the composite endpoint. Statistical analysis of the obtained data was performed using Microsoft Excel, IBM SPSS Statistics v.23. Results. A significant difference in echocardiographic data has been proved (p < 0.05) regarding left ventricle (LV) dimensions in both study groups. A significant decrease in the E/A ratio and an insignificant decrease in E/E’ (p > 0.05) have been found in the first group. When analyzing the indicators of diastolic function in the second group, a highly significant (p < 0.05) decrease in E/A, E/E’, IO of the LA has been revealed; data analysis on the morphofunctional state indicators of the extracranial arteries has shown a CIM reduction and a decrease in PSV and RI. Conclusions. Prescriptions of the fixed-dose combination of amlodipine with the ACE inhibitor lisinopril was more effective in terms of the LV measurements (p < 0.05) and LV diastolic function as evidenced by decreased E/A, E/E’ and IO of the LA (p < 0.05) as compared to the data in the group of amlodipine with the angiotensin 2 receptor blocker valsartan. Both fixed-dose combinations were effective in reducing the CIM thickness, decreasing PSV and RI when analyzing the morphofunctional state findings of the extracranial arteries.